Perfluorohexyloctane (NOV03) was able to reduce the signs and symptoms of dry eye disease (DED) when compared with hypotonic saline control and was well tolerated. Decreased signs and symptoms were ...

Richard Adler, MD, FACS, discusses corneal fluorescein staining data presented at AAO 2023 from the pooled analysis of 2 phase 3 studies. This is a video synopsis/summary of a Post Conference ...

MIEBO is the First and Only Prescription Eye Drop that Directly Targets Tear Evaporation, the Leading Cause of Dry Eye Disease DED affects more than 38 million Americans, with approximately nine in 10 ...

NOV03 is an investigational, water- and preservative-free nonsteroidal eye drop. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for NOV03 (perfluorohexyloctane) for ...

Phase 2 Study Published in Cornea: The Journal of Cornea and External Disease; Study Met Primary Endpoint in Patients with Highly Symptomatic Evaporative Dry Eye Disease Associated with Meibomian ...

HEIDELBERG, Germany, and CAMBRIDGE, Mass., Dec. 16, 2021 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water ...

Please provide your email address to receive an email when new articles are posted on . WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Laura M. Periman, MD, discusses ...

About NOV03 (perfluorohexyloctane) Ophthalmic Solution NOV03 is an investigational, proprietary, water-free, single-component preservative-free eye drop. 5 In 2019, Bausch + Lomb acquired an exclusive ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A single drop of Miebo had no significant impact on ...

LAVAL, QC and HEIDELBERG, Germany, July 7, 2021 /CNW/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and ...

NOV03 is Being Investigated to Treat the Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction VAUGHAN, Ontario & HEIDELBERG, Germany — Bausch + Lomb Corporation (NYSE/TSX: ...

MIEBO is the First and Only Prescription Eye Drop that Directly Targets Tear Evaporation, the Leading Cause of Dry Eye Disease VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading ...